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Since the acknowledgement of the reintroduction of the dengue virus 
in Brazil early in the eighties, the local population has been exposed to 
scenarios of extensive virus transmissions. The dengue epidemiology in 
Brazil during the last decade has been characterized by the occurrence of 
bursting epidemics, increase in the number of serious cases, displacement 
in the patient’s age group and simultaneous circulation of serotypes 1, 2 
and 3 and the recent introduction of serotype 41-3.
In this epidemiologic scenario, the potential availability of a vaccine 
that immunizes against the four dengue virus serotypes is a promissory 
condition, capable of reverting the worsening of the problem trend in 
this country. This assessment is based on two basic points: 
1.  Difficulty to implement current measures to control the Aedes aegypti 
vector, due to its low effectiveness or high cost4.
2.  Recognition of the capacity of the Immunization National Program in 
insuring high vaccine coverage, which is responsible for the reduction 
and even for the elimination of some immunopreventable diseases.
However, issues about safety, immunogenicity, efficacy and 
effectiveness, which are basic pre-requisites for the development of any 
vaccine, become more important when we deal with candidate vaccines 
against dengue. The peculiar aspects of the disease physiopathogeny, 
especially the potential risk of Antibody Enhancement Dependence 
(AED) further contribute to the complexity of such vaccines 
development.
This subject was recently given priority by the Health Ministry in 
Brazil that set up a workgroup composed of experts in different fields, 
whose main objective is to develop strategies for the introduction of 
the dengue vaccine in the Sistema Único de Saúde (Government health 
program). Among this group’s tasks, the definition of studies for the 
identification of priority areas and target groups who will receive the 
vaccine is outstanding, and should include a permanent channel for 
discussion about dengue candidate vaccines including public and private 
manufacturers.
This initiative of the Health Ministry matches other initiatives 
taken by different sectors. The most recent one occurred during the I 
International Symposium on Dengue sponsored by the Faculdade de 
Medicina da Universidade de São Paulo (São Paulo Medical School) 
in October 2011. In that symposium, the main findings concerning the 
recombinant dengue vaccine (YF17D) developed by the Sanofi Pasteur 
have been discussed.
The results of the discussions on the issues raised by the Symposium 
participants are described hereafter. Among the questions raised, 
the aspects connected with the vaccination schedule, adverse events 
associated with the vaccine, viscerotropism risk, immunogenicity degree 
for each dengue serotypes, reactogenicity to the vaccine in populations 
of endemic and non-endemic areas, possibility of immunization against 
the yellow fever virus and many others were marked issues. 
1. The candidate TDV is a tetravalent recombinant live vaccine. How 
we can guarantee that vaccine strains will not revert to wild dengue virus?
In contrast to what has been observed with live, classically-attenuated 
dengue vaccines, the four recombinant CYD dengue vaccine viruses 
(CYD-1, CYD-2, CYD-3 and CYD-4) are very stable. The YF17D 
vaccine genome, upon which the CYD viruses are based, is in fact 
remarkably stable, both in vivo and in vitro, which may be attributed to 
the low error-rate of the viral RNA polymerase, the enzyme responsible 
for replication. Moreover, the many attenuations in the non-structural 
genes of YF17D make the reversion to virulence impossible in practice. 
The full sequence of each of the CYD-1–4 genomes was established 
at various stages throughout the vaccine lot production process, the 
results of which demonstrate that the four CYD viruses display very 
high genetic stability5,6. 
2. What are the most frequent adverse events observed in immunized 
people? Can it cause dengue-like syndrome?
The most frequent adverse events are mild-to-moderate injection site 
pain, erythema, edema, headache, fever, malaise, asthenia and myalgia 
(14-40% after each vaccination). Injection site reactions were reported 
by a comparable proportion of participants after each injection of TDV. 
Systemic reactions appeared to be more frequent after the first TDV 
vaccination, and there is a trend towards progressively reduction of 
adverse events after each subsequently dose. Overall, adverse reactions 
are similar when compared to other single or multiple dose licensed 
vaccine given to control groups. No adverse events resembling dengue-
like syndrome have been reported5-7.
3. The Sanofi Pasteur dengue vaccine is based on a YF 17D backbone. 
What is the risk of viscerotropism and neurotropism after vaccination? 
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Given that the tropism of a flavivirus is associated with its envelope 
proteins, and that the CYD viruses have the envelope genes of dengue 
rather than those of the YF17D vaccine strain, these very rare adverse 
events after YF vaccination are not expected to occur after vaccination 
with the CYD dengue vaccine5,6. However, given the rarity of these events 
after YF vaccination, post-licensure studies will be able to provide the 
necessary statistical power to eliminate this theoretical risk. 
4. Is the immunogenicity for each dengue ST the same?
After three doses of TDV given six months apart, consistent and 
balanced antibody responses to all four serotypes are observed5,6. Some 
variability between serotypes are seen after first of the three doses, 
particularly in populations with no prior flaviviral immunity. 
5. Does the reactogenicity differ when TDV is given to people living 
in endemic or non endemic areas?
No, the local and systemic reactogenicity is very similar between 
participants living in non-endemic and endemic regions. Similarly, 
reactogenicity is not affected by whether the participants have a history 
of vaccination against another flavivirus.
6. Will the Sanofi Pasteur vaccine protect against both yellow fever 
and dengue?
No, the Sanofi Pasteur vaccine candidate is designed to protect only 
against dengue infection. The envelope and pre membrane genes that 
induce antibodies expressed by CYD strains are from dengue virus.
7. The formulation and schedule of vaccination recommended to 
children is the same of that indicated for adolescents and adults?
Yes, the formulation will be the same, and the vaccine will be licensed 
according the schedule used in PIII studies, with three doses (0-6 and 
12 months).
8. Are any differences in immunogenicity observed after 3rd dose of 
TDV when we compare children and adults? 
Immunogenicity is robust and balanced after 3rd dose in both children 
(> two years) and adults.
9. Why is the vaccination schedule not offered with a shorter interval 
between the doses? 
The immune response to dengue is serotype specific, but short-lasting 
cross-reactive antibodies (IgM or even IgG) triggered by the responding 
serotypes after one dose of live recombinant CYD dengue vaccine can 
still block at the time of a second dose vaccine serotypes which did 
not respond initially. A too short interval of time may then result in the 
inactivation of the booster dose because of these cross reactive antibodies, 
and/or by persistent innate responses (type I IFNs)8.
10. Does the immune response to dengue vaccine differ in dengue 
endemic versus non-endemic areas? 
Yes: a significant proportion of a population residing in an area where 
dengue is endemic will have developed an antibody response against 
dengue from natural infection prior to vaccination. This pre-existing 
response favors quicker and higher immune responses to CYD TDV, 
compared to the responses observed in a population who has not been 
exposed to dengue. 
11. Can the vaccine be used in children? What is the age for 
registration?
After approval, the initial indication will be for children aged two 
years or older. The possibility of vaccinating children younger than two 
years will depend on the outcome of co-administration studies.
12. Can dengue vaccine be administered with other vaccines 
recommended for children, adolescents and adults?
Clinical studies designed to answer this question are ongoing or 
are planned. For example, a study assessing the co-administration of 
tetravalent dengue vaccine with a combined measles-mumps-rubella 
vaccine is ongoing. The results of this study are expected in 2012.
13. Is there interference between yellow fever (YF) and dengue 
vaccines when used simultaneously? What is the immune response for 
each vaccine?
The potential interference between these two vaccines will be 
assessed. Ongoing safety and immunogenicity studies include co-
administration of TDV, YF and measles at nine months (Colombia and 
Peru) and MMR at 12 months of age, to evaluate. A study of Sanofi 
Pasteur’s recombinant, live, attenuated Japanese encephalitis vaccine, 
developed using the same recombinant technology as that used to develop 
the CYD vaccine (i.e., also based on the YF-17D backbone), designed 
specifically to assess the potential for interference between the two 
vaccines, concluded that they could be successfully co-administered 
simultaneously or 30 days apart. Of course, the outcome may differ for 
dengue, which is a tetravalent vaccine9.
14. What is the efficacy and duration of protection for each ST DEN 
1, 2, 3, 4?
As there is no known correlate of protection, the level of protective 
efficacy can only be determined in efficacy studies. Results from the 
first efficacy study are expected to be known before the end of 2012. 
Pre and post licensure clinical studies will provide data on long-term 
immune responses. 
15. Does SP intend to conduct new studies with two doses for people 
previously vaccinated with YF?
The program of development of the vaccine has focused on a three 
dose schedule to conservatively cover those individuals who may or not 
have had previous exposure to dengue or another flavivirus (natural or 
post-immunization).
16. How many dengue cases (DF and DHF) or deaths were confirmed 
after each dose of DTV?
In the initial studies already completed, there was no dengue like 
syndrome associated with DTV. Dengue cases are being followed in 
the efficacy studies in a blinded manner, and there is an Independent 
Monitoring Committee that analyses the signs for serious adverse events 
in clinical trials. In a recent study including children, adolescents and 
adults, four serious adverse events occurred (fatal traffic accident, partial 
seizures, hepatitis A infection, and upper respiratory tract infection), 
none of with were considered related to the vaccine by the investigators, 
the sponsor, or the independent monitoring committee7. Until now, with 
more then 11,000 people immunized, there was no alert sign to open 
the codes of studies5,10.
17. Will a booster be necessary after three doses? When?
For “travelers” living in non-endemic areas (no further contact with 
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the wt viruses), this is most likely (long-term follow up is needed to 
know when). 
In endemic regions, natural boosters caused by wt infections may 
be sufficient (again, data will come from long-term follow up studies 
in different areas)
18. What would be the best age to start vaccination?
As dengue affects people of all ages, the best age to start vaccination 
will be as soon as possible. The initial submission dossier will provide 
information about the vaccine for people > two years of age.
19. What are the contra indications for this vaccine?
As it contains live virus, it  will be contraindicated to 
immunocompromised people and pregnant women. It has not been 
studied in infants, and should not be administered for children < 24 
months of age.
20. Can the vaccine be used during outbreaks?
This question only can be answered after registration, because the 
phase III studies were developed to evaluate the efficacy after three doses 
(schedule 0, 1 and 6 months). We do not have data about efficacy using 
partial schedule.
Note - The opinions expressed by participants not necessarily have 
support by Ministry of Health.
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